Abstract 166P
Background
An estimated 841,000 new Hepatocellular Carcinoma (HCC) cases have been identified globally, with Asia having the highest incidence (73%). However, there is limited real world data on how HCC is diagnosed and on the preferred treatment modalities. This study aims to evaluate and compare the presentation and management patterns in patients with HCC across Hong Kong (HK), Singapore (SG) and Thailand (TH).
Methods
Primary research was conducted amongst key HCC therapeutic area experts within Asia Pacific. A total of 18 oncologists, hepatologists and gastrointestinal specialists (6 HK; 6 SG; 6 TH) participated in the qualitative phase and a total of 55 (15 HK; 20 SG; 20 TH) in the quantitative phase. Face-to-face interviews using a discussion guide (Qualitative phase) were conducted in August to October 2019 and structured questionnaires (Quantitative phase) were implemented in October to November 2019. We are presenting the descriptive statistics of the stage at diagnosis, comorbidities and treatment modalities of HCC patients based upon this study.
Results
The key therapeutic area experts reported that patients in Hong Kong and Singapore present at an advanced stage per the Barcelona Clinic Liver Cancer (BCLC) guidelines (Stage C: 76% HK; 63% SG; 45% TH) as compared to patients in Thailand. Cirrhosis was a key etiology in Singapore and Thailand (90%, 77%) and Hepatitis B in Hong Kong (89%). Targeted therapy was the preferred first-line HCC treatment in Hong Kong, Singapore and Thailand (89%, 84%, 88%). Immunotherapy was the preferred second-line HCC treatment in Hong Kong (64%). Chemotherapy was used first-line in Thailand (13%) and second-line in Hong Kong, Singapore and Thailand (3%, 11%, 24%).
Conclusions
The treatment patterns and presentation of HCC patients at diagnosis varies considerably across Hong Kong, Singapore and Thailand. These findings on real world practice will be useful to clinicians in understanding the trends and patterns in the diagnosis of HCC and developing treatment strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kantar.
Funding
IPSEN Pharmaceutical company.
Disclosure
P.K.H. Chow: Advisory/Consultancy: Sirtex Medical; Advisory/Consultancy: Ipsen; Advisory/Consultancy: Oncosil; Advisory/Consultancy: Bristol-Myers Squibb; Advisory/Consultancy: MSD; Advisory/Consultancy: Roche. J-F. Baladi, Y. Chia, B. Ramaswamy: Full/Part-time employment: Ipsen. V. Grillo, A. Acorda, K. Xu, S. Singh, Y. Chen, Y. Gilliam, R. Gowindah: Full/Part-time employment: Kantar.
Resources from the same session
163P - Gastrointestinal stromal tumours (GIST) in adolescents and young adults (AYA) in an Asian institution from 2002 to 2018
Presenter: Evelyn Yi Ting Wong
Session: e-Poster Display Session
164P - The impact of sarcopenia on chemotherapy toxicity and survival rate among hepatocellular carcinoma patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Elizabeth Marcella
Session: e-Poster Display Session
165P - Prognostic factors in sorafenib-treated hepatocellular carcinoma: Multicentre analysis of a European population sample
Presenter: João Gramaça
Session: e-Poster Display Session
167P - Epidemiology of hepatocellular carcinoma (HCC) in tertiary level hospitals in Bangladesh
Presenter: Abdullah Al Mamun Khan
Session: e-Poster Display Session
168P - Response assessments in hepatocellular carcinoma: What are the best criteria to utilize? mRECIST or RECIST 1.1? A retrospective meta-analysis of multiple phase III trials
Presenter: Oliver Bohnsack
Session: e-Poster Display Session
169P - IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCC
Presenter: Masatoshi Kudo
Session: e-Poster Display Session
170P - Sintilimab plus anlotinib as first-line therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC)
Presenter: Xiaofeng Chen
Session: e-Poster Display Session
171P - Transarterial chemoembolization (TACE) plus lenvatinib versus TACE plus sorafenib for hepatocellular carcinoma (HCC) with portal vein tumour thrombus (PVTT): A prospective randomized study
Presenter: Xiaoyan Ding
Session: e-Poster Display Session
172P - Triple combination therapy of lenvatinib, toripalimab, and hepatic arterial infusion chemotherapy versus lenvatinib for advanced hepatocellular carcinoma
Presenter: Zhi-Cheng Lai
Session: e-Poster Display Session
173P - Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Asia: Interim results from the observational REFINE study
Presenter: Ho Yeong Lim
Session: e-Poster Display Session